Evaluating the Pieces of the Pharma Supply Chain - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Evaluating the Pieces of the Pharma Supply Chain
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role? This article contains bonus online-exclusive material.

Pharmaceutical Technology
Volume 33, Issue 1

Legislative proposals. Last April, US Representatives John Dingell (D-MI), Frank Pallone, Jr. (D-NJ), and Bart Stupak (D-MI) issued a discussion draft of the Food and Drug Administration Globalization Act of 2008 to improve the FDA inspection process (10). Revised in July, the discussion draft proposes that:

  • All drug facilities operating within the US or exporting products to the US register with FDA annually (a registration fee would generate resources for inspections)
  • FDA inspect foreign and domestic facilities every two to four years, provided sufficient information has been given to the agency to assess risk (a manufacturer would not be able introduce a drug or ingredient into the marketplace until an initial facility inspection has been conducted)
  • Restrictions be placed on the entry of imports that lack safety documentation
  • Drug establishments implement a quality riskmanagement plan
  • Manufacturers test and verify drug identity and purity
  • FDA issue fines for violations of drug-safety requirements; the agency's authority would be extended to recall and detain dangerous drugs as well as to destroy counterfeit or adulterated imports
  • Electronic pedigrees document a drug's supply chain
  • Country-of-origin labeling identify the source of APIs and their place of manufacture (11).

Although the Globalization Act is still circulating as a proposal within Congress, FDA Press Officer Christopher C. Kelly says the agency is already tweaking its inspection process to be more global in nature. "We are putting an emphasis on the supply chain during the regular course of our good manufacturing practice inspections and preapproval inspections," he says. "We are looking at sourcing and actively participating in industry conferences and professional forums on the topic as well as attempting to increase our coverage." FDA is opening up several offices abroad and dedicating more inspectors for foreign plants.

The agency is also improving its system for registration of foreign facilities. The FDA Foreign Facility Registration Verification Project is meant to establish a contract relationship with nongovernmental organizations that have an office overseas that can verify, as trusted FDA agents, the registration data of foreign firms that are shipping to the US. "The process will include visiting the foreign firms, verifying, and documenting the existence of the firms, and confirming the firms manufacture the products that FDA import records indicate the firms export to the US," explains Kelly. The project is expected to include, but not be limited to China, India, and Mexico.

Dingell plans to introduce a bill ref lecting the revised discussion draft in the House Energy and Commerce Committee early this year (12). Some industry groups are voicing concerns on certain aspects of the proposed legislation.

The International Pharmaceutical Excipients Council (IPEC), for example, plans to submit written comments to the committee about the Act's proposals. Although IPEC is supportive of the fact that the Act, if passed, would put more pressure on what a user needs to do to qualify its suppliers, the organization is concerned about the bill's call for a nofee registration of excipient plants.

"There should be a fee for them just like there is for API facilities," says David R. Schoneker, who ended his term as chairman of IPEC–Americas on Jan. 1. Schoneker is also a member of Pharmaceutical Technology's editorial advisory board. "If you have a registration process that only involves an Internet form and a registration number, well, the bad guys can do that too. Some may try to tout the fact that they have an FDA registration number as if they've been FDA-approved. A reasonable fee is necessary, and pharmaceutical companies should only be allowed to use excipients from registered excipient suppliers."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here